A widely prescribed class of blood pressure medications, dihydropyridine calcium channel blockers (DCCBs), may be associated with an increased risk of kidney damage in individuals with type 2 diabetes, even when they are already taking kidney protective treatments. This finding, presented at the Annual Congress of the European Kidney Association, raises important questions about current treatment strategies for diabetic kidney disease (DKD).
Key takeaways
- Dihydropyridine calcium channel blockers (DCCBs), commonly used to control blood pressure, may increase the risk of kidney damage in people with type 2 diabetes.
- Patients taking DCCBs in combination with standard kidney protection therapies (RAS inhibitors and SGLT2 inhibitors) showed a 33% increased risk of major adverse kidney events.
- The mechanism may involve DCCBs altering blood flow dynamics within the kidney, which may lead to increased pressure.
- Researchers stress that more studies are needed to confirm these findings and guide treatment decisions.
Understand the risks
Diabetic kidney disease (DKD) is a major complication of type 2 diabetes, often leading to… Kidney failure. Managing blood pressure is crucial in slowing its progression. For many years, renin-angiotensin system (RAS) and sodium-glucose cotransporter 2 (SGLT2) inhibitors have been the cornerstone of treatment for chronic kidney disease (DKD), providing significant kidney protection.
However, the new research, which analyzed data from more than 31,000 adults with type 2 diabetes between 2016 and 2021, suggests that adding DCCBs to these standard treatments may counteract some of their benefits. Patients taking DCCBs in addition to RAS and SGLT2 inhibitors had a 33% increased risk of adverse kidney events, defined as a significant reduction in kidney filtration capacity or progression to end-stage renal disease requiring dialysis or transplantation.
Potential mechanisms and future directions
Researchers hypothesize that DCCBs may contribute to kidney damage by relaxing blood vessels leading to the kidneys without affecting those carrying blood away. This can lead to increased pressure within the kidney’s filtering units, exacerbating existing damage.
Although the study was observational and cannot conclusively prove causality, the results are considered clinically significant due to the widespread use of DCCBs. Lead researcher Dr. Timna Aghor stressed that patients should not stop taking their medications without consulting a doctor. Further prospective studies and randomized controlled trials are necessary to confirm these observations and identify safer and more effective blood pressure management strategies for individuals with diabetes.
Lifestyle factors remain crucial
Besides medications, lifestyle modifications play a vital role in managing blood pressure and kidney health in individuals with diabetes Type 2 diabetes. These include maintaining a healthy weight, reducing sodium intake, getting regular physical activity, eating potassium-rich foods, limiting alcohol, managing stress, and ensuring adequate sleep. Regular monitoring of kidney function is also essential for early detection and intervention.
